Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Pradofloxacin is a third-generation fluoroquinolone, licensed in the EU for use in a range of indications in the dog and cat and authorized more recently in the USA for one therapeutic indication (skin infections) in the cat. This review summarizes and appraises current knowledge on the...

Author(s)
Lees, P.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Journal of Veterinary Pharmacology and Therapeutics, 2013, 36, 3, pp 209-221
Abstract

A 4-year-old domestic shorthair cat was presented with a 7-month history of nodules and draining fistulous tracts of the ventral abdomen. Histopathological examination of affected tissue revealed acid-fast bacilli stained by the Ziehl-Neelsen procedure. Deep tissue culture confirmed infection with...

Author(s)
Cox, A.; Udenberg, T. J.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Veterinary Journal, 2020, 61, 1, pp 39-43
Abstract

ComPath is a pan-European resistance monitoring programme collecting bacterial pathogens from dogs and cats. We present data for respiratory tract infection (RTI) isolates collected between 2008 and 2010. Antimicrobial minimal inhibitory concentrations (MICs) were determined and susceptibility...

Author(s)
Morrissey, I.; Moyaert, H.; Jong, A. de; El-Garch, F.; Klein, U.; Ludwig, C.; Thiry, J.; Youala, M.
Publisher
Elsevier B. V., Amsterdam, Netherlands
Citation
Veterinary Microbiology, 2016, 191, pp 44-51
Abstract

Aims: To present antimicrobial susceptibilities for bacteria from dogs and cats with respiratory tract infection (RTI) across Europe in 2013-2014 and compare with data from 2008-2010. Methods and results: Minimal inhibitory concentrations were determined for 464 isolates following Clinical and...

Author(s)
Moyaert, H.; Jong, A. de; Simjee, S.; Rose, M.; Youala, M.; El-Garch, F.; Vila, T.; Klein, U.; Rzewuska, M.; Morrissey, I.
Publisher
Wiley, Oxford, UK
Citation
Journal of Applied Microbiology, 2019, 127, 1, pp 29-46
Abstract

Background: Pradofloxacin, a newly developed 8-cyano-fluoroquinolone, show enhanced activity against Gram-positive organisms and anaerobes to treat canine and feline bacterial infections. The purpose of this cross-over study was to measure the unbound drug concentration of pradofloxacin in the...

Author(s)
Hauschild, G.; Rohn, K.; Engelhardt, E.; Sager, M.; Hardes, J.; Gosheger, G.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2013, 9, 32, pp (14 February 2013)
Abstract

Objective - To evaluate the efficacy of the fluoroquinolone pradofloxacin in the treatment of cats experimentally infected with Mycoplasma hemofelis. Animals - 23 young adult specific-pathogen-free cats. Procedures - Cats were inoculated with M. hemofelis from a chronically infected donor and...

Author(s)
Dowers, K. L.; Tasker, S.; Radecki, S. V.; Lappin, M. R.
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
American Journal of Veterinary Research, 2009, 70, 1, pp 105-111
Abstract

Background: Upper respiratory tract disease (URTD) of cats is caused by a number of pathogens, including Chlamydophila felis and Mycoplasma spp. For effective treatment of both infections, doxycycline and enrofloxacin are recommended, but adverse effects limit their use in cats. Hypothesis: That...

Author(s)
Hartmann, A. D.; Helps, C. R.; Lappin, M. R.; Werckenthin, C.; Hartmann, K.
Publisher
Blackwell Publishing, Oxford, UK
Citation
Journal of Veterinary Internal Medicine, 2008, 22, 1, pp 44-52
Abstract

Pradofloxacin is a new veterinary 8-cyano-fluoroquinolone developed for use against bacterial infections in dogs and cats involving both aerobic and anaerobic bacteria. The minimal bactericidal concentrations have been determined against clinical isolates of Staphylococcus pseudintermedius, ...

Author(s)
Silley, P.; Stephan, B.; Greife, H. A.; Pridmore, A.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Microbiology, 2012, 157, 1/2, pp 106-111
Abstract

Rapidly growing mycobacteria (RGM) and Nocardiae can cause severe or refractory infections in cats and dogs. Prolonged antibacterial therapy is required to cure these infections. As fluoroquinolones have been used in combination therapy for treating RGM infections, isolates from the Mycobacterium...

Author(s)
Govendir, M.; Norris, J. M.; Hansen, T.; Wigney, D. I.; Muscatello, G.; Trott, D. J.; Malik, R.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Microbiology, 2011, 153, 3/4, pp 240-245
Abstract

In this study, 908 bacterial pathogens from defined infections of dogs and cats were tested for their susceptibility to the novel fluoroquinolone pradofloxacin, which was approved in 2011 for use in cats and dogs. Most of the bacteria tested (Staphylococcus aureus, Staphylococcus pseudintermedius, ...

Author(s)
Schink, A. K.; Kadlec, K.; Hauschild, T.; Michael, G. B.; Dörner, J. C.; Ludwig, C.; Werckenthin, C.; Hehnen, H. R.; Stephan, B.; Schwarz, S.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Microbiology, 2013, 162, 1, pp 119-126

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics